[Skip to Content]
[Skip to Content Landing]
Citations 0
Lab Reports
April 7, 2010

Metastatic Prostate Cancer

JAMA. 2010;303(13):1245. doi:10.1001/jama.2010.351

Scientists at the University of California, San Diego, in La Jolla have found that androgen ablation therapies used to treat prostate cancer may indirectly promote the development of metastatic androgen-independent secondary tumors (Ammirante M et al. Nature. doi:10.1038/nature08782 [published online ahead of print March 10, 2010]). These tumors are responsible for most deaths due to prostate cancer.